New possibilities of using moxonidin for blood pressure control in female patients with osteopenia

Objective: To assess the effect of moxonidine on bone metabolism and bone mineral density (BMD) in postmenopausal patients with arterial hypertension (AH) and osteopenia. Materials and methods: A randomized, open, clinical trial included 114 postmenopausal patients with AH. All participants were evaluated bone metabolism), BMD, telomerase activity (TA). Randomization was carried out into 2 groups (moxonidine and bisoprolol therapy) using simple envelopes. After 12 months of therapy, a dynamic examination was performed. Results: Both groups showed a positive effect of both moxonidine and bisoprolol on hypertension during treatment both as monotherapy and in the group of patients receiving combined antihypertensive therapy: a decrease in SBP and DBP in the 1st group was 13.6% and 12.8% respectively, and in the 2nd group - 13.7% and 15% respectively, while achieving normal values. In most patients of group 1, normalization of body weight was noted in comparison with group 2 (23.4% and 17.4%, respectively, p = 0.043), delta of body weight in the moxonidine group was -1.89%. The increase in the processes of bone formation in the form of increased markers of OC and Osteoprotegerin and a statistically significant increase in TA in patients receiving moxonidine were revealed, while in women who took bisoprolol there were no dynamic changes in bone metabolism rates, there was a tendency for a decrease in BMD and a significant decrease in AT. Conclusions: The detected pleiotropic effect of moxonidine on bone metabolism and replicative cell aging processes will reduce the risk of development or progression of osteopenia and osteoporosis in postmenopausal women with AH.

моксонидин, артериальная гипертония, остеопороз, остеопения, костный метаболизм, moxonidine, arterial hypertension, osteoporosis, osteopenia, bone metabolism

1. Чазова И. Е., Ратова Л. Г., Бойцов С. А., Небиеридзе Д. В., Карпов Ю. А., Белоусов Ю.Б. и др. Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по АГ и Всероссийского научного общества кардиологов). Системные Гипертензии. 2010; (3):5-26.

2. Tangri N., Kitsios GD, Inker LA, Griffith J., Naimark DM, Walker S. et al. Risk Prediction Models for Patients With Chronic Kidney Disease: A Systematic Review. Annals of Internal Medicine. 2013;158 (8):596. DOI: 10.7326/0003-4819-158-8-201304160-00004

3. Gkaliagkousi E., Gavriilaki E., Doumas M., Petidis K., Aslanidis S., Stella D. Cardiovascular Risk in Rheumatoid Arthritis: Pathogenesis, Diagnosis, and Management. Journal of Clinical Rheumatology. 2012;18 (8):422-30. DOI:10.1097/RHU. 0b013e31827846b1

4. Weiss IA, Bloomgarden N., Frishman W.H. Subclinical Hypothyroidism and Cardiovascular Risk: Recommendations for Treatment. Cardiology in Review. 2011;19 (6):291-9. DOI:10.1097/CRD. 0b013e318227df87

5. Vassalle C., Sabatino L., Cecco PD, Maltinti M., Ndreu R., Maffei S. et al. Relationship between Bone Health Biomarkers and Cardiovascular Risk in a General Adult Population. Diseases. 2017;5 (4):24. DOI: 10.3390/diseases5040024

6. Hyder JA, Allison MA, Wong N., Papa A., Lang TF, Sirlin Cet al. Association of Coronary Artery and Aortic Calcium With Lumbar Bone Density: The MESA Abdominal Aortic Calcium Study. American Journal of Epidemiology. 2008;169 (2):186-94. DOI:10.1093/aje/kwn303

7. Naves M., Rodriguez-Garcia M., Diaz-Lopez JB, Gomez-Alonso C., Cannata-Andia J.B. Progression ofvascular calcifications is associated with greater bone loss and increased bone fractures. Osteoporosis International. 2008;19 (8):1161-6. DOI:10.1007/s00198-007-0539-1

8. Blackburn EH, Greider CW, Szostak J.W. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nature Medicine. 2006;12 (10):1133-8. DOI:10.1038/nm1006-1133

9. Chen C-I, Yeh J-S, Tsao N-W, Lin F-Y, Shih C-M, Chiang K-H et al. Association between renin - angiotensin - aldosterone system blockade and future osteoporotic fracture risk in hypertensive population: A population-based cohort study in Taiwan. Medicine. 2017;96 (46):e8331. DOI:10.1097/MD. 0000000000008331

10. Ikeda K. Renin-aldosterone and bone metabolism. Clin Calcium. 2014;24 (6):885-91. DOI: CliCa1406885891

11. Assaf AR, Bushmakin AG, Joyce N., Louie MJ, Flores M., Moffatt M. The Relative Burden of Menopausal and Postmenopausal Symptoms versus Other Major Conditions: A Retrospective Analysis of the Medical Expenditure Panel Survey Data. Am Health Drug Benefits. 2017;10 (6):311-21. PMID:28975014

12. Xiao X., Xu Y., Wu Q. Thiazide diuretic usage and risk of fracture: a metaanalysis of cohort studies. Osteoporosis International [Internet]. 2018 [cited 2018]; DOI:10.1007/s00198-018-4486-9

13. Cobos-Puc LE, Sanchez-Lopez A., Centurion D. Pharmacological analysis of the cardiac sympatho-inhibitory actions of moxonidine and agmatine in pithed spontaneously hypertensive rats. European Journal of Pharmacology. 2016;791:25-36. DOI:10.1016 /j. ejphar. 2016.08.017

14. Дудинская Е. Н., Ткачева О. Н. Дополнительные преимущества антигипертензивной терапии моксонидином у женщин с АГ в период постменопаузы. Кардиоваскулярная терапия и профилактика. 2014;13 ( 1 ):8-15.

15. Дудинская Е. Н., Ткачева О. Н. Перспективы использования моксонидина (Физиотенза®) в профилактике костной резорбции и старения сосудистой стенки. Терапия. 2016; (4):114-20.

16. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266 (5193):2011-5. PMID:7605428

17. Остеопороз. Руководство. Лесняк О. М., editor. - М.: ГЭОТАР-Медиа; 2016. 464 p. ISBN: 978-5-9704-3986-9

18. Bogacka I., Xie H., Bray GA, Smith S.R. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes. 2005;54 (5):1392-9. PMID:15855325

19. Silva I., Branco J.C. Rank/Rankl/opg: literature review. Acta Reumatol Port. 2011;36 (3):209-18. PMID :22113597

20. Quercioli A., Montecucco F., Bertolotto M., Ottonello L., Pende A., Mach F. et al. Coronary artery calcification and cardiovascular risk: the role of RANKL/OPG signalling: CALCIUM SCORE AND CARDIOVASCULAR RISK. European Journal of Clinical Investigation. 2010;40 (7):645-54. DOI:10.1111/j. 1365-2362.2010.02308. x